ALTEOGEN Inc (196170) - Total Liabilities

Latest as of September 2025: ₩261.55 Billion KRW ≈ $177.25 Million USD

Based on the latest financial reports, ALTEOGEN Inc (196170) has total liabilities worth ₩261.55 Billion KRW (≈ $177.25 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALTEOGEN Inc operating cash flow efficiency to assess how effectively this company generates cash.

ALTEOGEN Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how ALTEOGEN Inc's total liabilities have evolved over time, based on quarterly financial data. Check 196170 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

ALTEOGEN Inc Competitors by Total Liabilities

The table below lists competitors of ALTEOGEN Inc ranked by their total liabilities.

Company Country Total Liabilities
Argen-X
LSE:0QW0
UK €679.80 Million
Investment AB Latour (publ)
ST:LATO-B
Sweden Skr27.54 Billion
mBank SA
WAR:MBK
Poland zł258.84 Billion
Juniper Networks Inc
NYSE:JNPR
USA $5.26 Billion
Shengyi Electronics Co. Ltd. A
SHG:688183
China CN¥4.46 Billion
Ovintiv Inc
NYSE:OVV
USA $9.15 Billion
Focus Media Information Technology Co Ltd
SHE:002027
China CN¥6.96 Billion
Bharat Heavy Electricals Limited
NSE:BHEL
India Rs475.72 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down ALTEOGEN Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALTEOGEN Inc (196170) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.41 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ALTEOGEN Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ALTEOGEN Inc (2014–2024)

The table below shows the annual total liabilities of ALTEOGEN Inc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩134.92 Billion
≈ $91.43 Million
+24.63%
2023-12-31 ₩108.26 Billion
≈ $73.37 Million
+11.92%
2022-12-31 ₩96.73 Billion
≈ $65.55 Million
-21.74%
2021-12-31 ₩123.61 Billion
≈ $83.77 Million
+340.77%
2020-12-31 ₩28.04 Billion
≈ $19.00 Million
+75.31%
2019-12-31 ₩16.00 Billion
≈ $10.84 Million
+236.41%
2018-12-31 ₩4.76 Billion
≈ $3.22 Million
+50.08%
2017-12-31 ₩3.17 Billion
≈ $2.15 Million
+16.44%
2016-12-31 ₩2.72 Billion
≈ $1.84 Million
+226.01%
2015-12-31 ₩834.62 Million
≈ $565.61K
-60.88%
2014-12-31 ₩2.13 Billion
≈ $1.45 Million
--

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$13.36 Billion
₩19.71 Trillion KRW
Market Cap Rank
#1772 Global
#43 in Korea
Share Price
₩368500.00
Change (1 day)
-3.03%
52-Week Range
₩317500.00 - ₩559000.00
All Time High
₩559000.00
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more